Professor Mina Ryten is a clinician scientist with a long-standing interest in the use of human brain transcriptomics to understand neurological diseases. Mina began her medical training in Cambridge University and went on to complete an MBPhD at UCL. While her PhD focused on purinergic signalling in skeletal muscle development, she subsequently trained in bioinformatics through an MRC Post-doctoral Fellowship in Systems Biology focusing on the genetic regulation of gene expression in human brain. This experience led her to become a Clinical Geneticist and formed the basis of her MRC Clinician Scientist Fellowship. Since 2017 Mina has led her own research group at the UCL Institute of Neurology, and later the UCL Institute of Child Health. In January 2024 Mina's lab moved to the University of Cambridge, where she also became the Director of the Cambridge Dementia Research Institute. At the core of her group's research is the use of human brain transcriptomic data as a genome-wide functional read-out of an individual's DNA – a read-out which can inform our understanding of the genetic origins of neurodegenerative diseases. In the context of complex neurological diseases, Mina has generated and used regulatory data across the human brain to link disease risk positions to specific genes. Focusing on rare neurogenetic diseases, she has used correlations in transcriptomic data to identify hidden gene-gene relationships, and more recently has applied RNA-sequencing technologies to patient derived-samples with diagnostics and novel therapeutics in mind. Thus, over the last ten years, she has developed extensive expertise in the generation and use of transcriptomic data with a specific focus on inherited neurological diseases.